Finanzen von YD Bio Ltd (YDES)YDESYD Bio Ltd

Evaluating the bottom line, YD Bio Ltd maintains a gross margin of 28.05%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -882.74%, while the net margin is -1392.61%. These profitability ratios, combined with a Return on Equity (ROE) of -445.10%, provide a clear picture of how effectively YDES converts its operational activities into shareholder value.

In the context of the broader market, YDES competes directly with industry leaders such as PROF and CATX. With a market capitalization of $262.78M, it holds a significant position in the sector. When comparing efficiency, YDES's gross margin of 28.05% stands against PROF's 78.41% and CATX's 100.00%. Such benchmarking helps identify whether YD Bio Ltd is trading at a premium or discount relative to its financial performance.

YDES has shown a gross margin of 30.44% for Q4 2024, indicating some operational efficiency, but it also has a concerning net margin of -276.58% for the same period, reflecting significant losses.